Abstract
AbstractProstate cancer is a heterogeneous disease process with a wide spectrum of clinicopathologic variables that impact diagnosis, risk stratification, and management. To improve diagnostic accuracy and to better inform clinical decision making, the development of molecular biomarkers has undergone considerable discovery and clinical validation in the past decade. Prostate cancer is no longer seen as a single disease entity but one with considerable heterogeneity existing between tumors and between patients. Biomarkers now allow for more personalized and precision‐based approaches to management that otherwise would have depended on applying clinical algorithms alone. The aim of this review is to discuss and evaluate prostate cancer tissue‐based biomarkers that have been developed to aid diagnosis, improve risk stratification, and management.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
